CXCR2-IN-1
CAS No. 1873376-49-8
CXCR2-IN-1 ( —— )
产品货号. M12902 CAS No. 1873376-49-8
一种有效的 CNS 渗透性 CXCR2 拮抗剂,pIC50 为 9.3;显示中性粒细胞趋化性抑制,pIC50 为 7.6。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥708 | 有现货 |
|
| 10MG | ¥1169 | 有现货 |
|
| 25MG | ¥2306 | 有现货 |
|
| 50MG | ¥3776 | 有现货 |
|
| 100MG | ¥5211 | 有现货 |
|
| 200MG | ¥7038 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CXCR2-IN-1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的 CNS 渗透性 CXCR2 拮抗剂,pIC50 为 9.3;显示中性粒细胞趋化性抑制,pIC50 为 7.6。
-
产品描述A potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6; has developability profiles (CYP inhibition pIC<5.0, and hERG binding affinity pIC<4.0); exhibits favorable PK profile, reasonable CNS penetration, and good developability potential; orally bioavailable.
-
体外实验CXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation. CXCR2-IN-1 (compound 22) shows favorable central nervous system penetration property (Br/Bl>0.45).
-
体内实验CXCR2-IN-1 shows efficacy in a cuprizone-induced demyelination model through oral administration, providing evidence to support CXCR2 to be a potential therapeutic target to treat demyelinating diseases such as multiple sclerosis.
-
同义词——
-
通路GPCR/G Protein
-
靶点Chemokine Receptor
-
受体Chemokine Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number1873376-49-8
-
分子量476.3492032
-
分子式C19H20Cl2FN3O4S
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥5.4 mg/mL (Need ultrasonic and warming)
-
SMILESCN1CCC(CC1)S(=O)(=O)C2=C(C=CC(=C2O)NC(=O)NC3=C(C(=CC=C3)F)Cl)Cl
-
化学全称Urea, N-(2-chloro-3-fluorophenyl)-N'-[4-chloro-2-hydroxy-3-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Xu H, et al. ACS Med Chem Lett. 2016 Feb 8;7(4):397-402.
产品手册
关联产品
-
Plerixafor
Plerixafor (JM-3100、AMD-3100、SID-791) 是一种有效的选择性 CXCR4 抑制剂。
-
CXCR2-IN-68
CXCR2-IN-68 是一种有效、选择性、脑渗透性、口服生物可利用的 CXCR2 拮抗剂,pIC50 为 9.0。
-
Ladarixin sodium
一种新型变构、非竞争性双重 CXCR1/2 抑制剂,可在体外抑制人多形核白细胞 (PMN) 迁移至 CXCL8,IC50 为 0.7 nM。
021-51111890
购物车()
sales@molnova.cn

